Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the mechanisms of HBV cccDNA creation, maintenance, and elimination
- Describe the impact of current antiviral therapies on the rate of HBsAg seroconversion and HBV cccDNA suppression
- Discuss the impact of current antiviral therapies on the rate of disease progression and the development of hepatocellular carcinoma
- Relate how and when reactivation from anti-HBs and anti-HBc positivity to HBsAg positivity occurs
Topics covered include:
- Introduction
- What Is cccDNA?
- cccDNA as a Therapeutic Target
- Is There a Role for cccDNA in Predicting the Response to Antiviral Therapy?
- What Is the Rate of HBsAg Loss With Current Therapies?
- Evidence for Lack of Cure: Reactivation With Seroreversion From Anti-HBs and Anti-HBc Positivity to HBsAg Positivity
- Which Patients Are at Risk for HBsAg Seroreversion?
- Clinical Presentation and Management of HBV HBsAg Seroreversion With Clinical Reactivation
- Can HBsAg Seroreversion and Reactivation Be Prevented?
- Summary: Implications for Clinical Practice